secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0000950103-21-017730
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Laboratories promotes Birgit Girshick to COO, adds Research Models & Services oversight
--------------------------------------------------------------------------------

- Birgit Girshick promoted to Executive VP and COO, effective November 11, 2021.
- She adds Research Models and Services to her existing responsibilities for Discovery, Safety Assessment, Biologics Solutions, and Cell & Gene Therapy CDMO.
- Girshick has been with Charles River since 1989, leading strategic initiatives and integrating acquisitions like Cognate BioServices and Vigene Biosciences.
- James C. Foster remains Chairman, President and CEO; his employment agreement was extended to February 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000095010321017730/0000950103-21-017730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000095010321017730/dp161684_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-21-017730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer